State of health in China - statistics & facts

In tandem with the country’s economic progress, the overall public health of the Chinese population improved significantly in the past decades. China now has a public healthcare system covering 90 percent of its citizens, and Chinese people are living longer with better access to more affordable and higher-quality health services. While the prevention of infectious diseases has been effective, the treatment of chronic diseases, and the care of the country’s aging population, continue to pose substantial challenges to the country’s healthcare system.

Re-engineering the medical care system

To provide all citizens with basic healthcare services while being financially protected, the Chinese government launched a reform to its health system in 2009. Major efforts were made in introducing cost-effective public health programs, establishing a universal health insurance scheme, and strengthening the infrastructures of the health service. These policies have reduced out-of-pocket (OOP) health payments with government subsidies, despite gaps in the quality of care, depending on socioeconomic status and region.

The epidemiological transition

China is going through a progressive shift in the health burden from infectious illnesses to chronic non-communicable diseases (NCDs). On one hand, apart from HIV/AIDS and tuberculosis, the mortality rates of most infectious diseases in China were reduced to levels below 0.05 per 100,000 population in 2021. On the other hand, unhealthy lifestyle, rising obesity, and the country’s rapidly aging population resulted in an ever-increasing upward trend in chronic diseases. Cancers, heart diseases, and cerebrovascular diseases were the leading underlying causes of death among of Chinese citizens. China is now facing a pressing demand for long-term healthcare for patients with NCDs, which would push the annual healthcare expenditure to over 1.5 trillion U.S. dollars by 2024. 

The COVID-19 pandemic

Despite China’s initial achievements in containing the spread of the virus and a successful mass vaccination program, China's Zero-COVID policy eventually became unsustainable after three years of disruptions. The socio-economic impacts of the lockdowns and multiple lockdown-related accidents sparked protests in December 2022 in several cities. Subsequently, the Chinese authorities quickly lifted almost all COVID control measures, leading to waves of infections across the country. Given the different definitions of the cause of death in China, the extent of the pandemic's impact and the number of Chinese victims lost to COVID-19 remains unclear.
This text provides general information. Statista assumes no liability for the information given being complete or correct. Due to varying update cycles, statistics can display more up-to-date data than referenced in the text.
Published by Wenyi Zhang, Jun 19, 2023

Key insights

Number of people aged above 65 years
210m
Public expenditure on health care and hygiene
2.25tr CNY
Leading Chinese biotech and pharmaceutical company
China Resources Pharmaceutical Group
Get more insights

Editor’s Picks Current statistics on this topic

Life expectancy at birth in China from 1960 to 2021 with forecasts until 2050 (in years)

Demographics

Life expectancy in China 1960-2050

Death rate of the most common chronic diseases in urban China in 2021 (per 100,000 population)

Diseases

Mortality rate of most common chronic diseases in urban China 2021

Ranking of infectious diseases in China in 2021, by mortality rate per 1,000,000 population

Diseases

Infectious diseases in China 2021, by mortality rate

Related topics

Recommended

6

Recommended statistics

Key indicators

6

Key indicators

Communicable diseases

8

Communicable diseases

Chronic diseases

6

Chronic diseases

Other common health issues

9

Other common health issues

Further reportsGet the best reports to understand your industry

Medical technology industry in China
Medical technology industry in China
Pharmaceutical industry in China
Pharmaceutical industry in China
Vaccine industry in China
Vaccine industry in China
Coronavirus (COVID-19) in China
Coronavirus (COVID-19) in China
Diabetes in China
Diabetes in China

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)
Email
support@statista.com

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)
Email
asia.support@statista.com

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)
Email
support.japan@statista.com

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)
Email
eu.support@statista.com

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)
Email
latam@statista.com

Mon - Fri, 9am - 6pm (EST)

Menu